Literature DB >> 30386969

Estimation for an accelerated failure time model with intermediate states as auxiliary information.

Ritesh Ramchandani1, Dianne M Finkelstein2, David A Schoenfeld2.   

Abstract

The accelerated failure time (AFT) model is a common method for estimating the effect of a covariate directly on a patient's survival time. In some cases, death is the final (absorbing) state of a progressive multi-state process, however when the survival time for a subject is censored, traditional AFT models ignore the intermediate information from the subject's most recent disease state despite its relevance to the mortality process. We propose a method to estimate an AFT model for survival time to the absorbing state that uses the additional data on intermediate state transition times as auxiliary information when a patient is right censored. The method extends the Gehan AFT estimating equation by conditioning on each patient's censoring time and their disease state at their censoring time. With simulation studies, we demonstrate that the estimator is empirically unbiased, and can improve efficiency over commonly used estimators that ignore the intermediate states.

Entities:  

Keywords:  AFT; Multi-state model; Semiparametric; Survival; Transition probabilities

Mesh:

Year:  2018        PMID: 30386969      PMCID: PMC6494714          DOI: 10.1007/s10985-018-9452-5

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  11 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Induced smoothing for rank regression with censored survival times.

Authors:  B M Brown; You-Gan Wang
Journal:  Stat Med       Date:  2007-02-20       Impact factor: 2.373

3.  Nonparametric estimation of transition probabilities in a non-Markov illness-death model.

Authors:  Luís Meira-Machado; Jacobo de Uña-Alvarez; Carmen Cadarso-Suárez
Journal:  Lifetime Data Anal       Date:  2006-08-18       Impact factor: 1.588

4.  Nonparametric estimation of transition probabilities in the non-Markov illness-death model: A comparative study.

Authors:  Jacobo de Uña-Álvarez; Luís Meira-Machado
Journal:  Biometrics       Date:  2015-03-02       Impact factor: 2.571

5.  Induced smoothing for the semiparametric accelerated failure time model: asymptotics and extensions to clustered data.

Authors:  Lynn M Johnson; Robert L Strawderman
Journal:  Biometrika       Date:  2009-06-25       Impact factor: 2.445

6.  A Monte Carlo method for variance estimation for estimators based on induced smoothing.

Authors:  Zhezhen Jin; Yongzhao Shao; Zhiliang Ying
Journal:  Biostatistics       Date:  2014-05-07       Impact factor: 5.899

7.  A model-informed rank test for right-censored data with intermediate states.

Authors:  Ritesh Ramchandani; Dianne M Finkelstein; David A Schoenfeld
Journal:  Stat Med       Date:  2015-01-13       Impact factor: 2.373

8.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

9.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

10.  Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis.

Authors:  James D Berry; Jeremy M Shefner; Robin Conwit; David Schoenfeld; Myles Keroack; Donna Felsenstein; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jeffrey D Rothstein; David J Greenblatt; Merit E Cudkowicz
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.